Paris 2 Nice

In September 2023, Laura Carroll, Kamilla Flynn, Tanya Knott, Mary Looby, Caitriona O’Brien, Emma Quinn and David Malone will cycle 700km over 6 days from Paris to Nice. All funds raised from this challenge with go towards The SJK Ralston Project to support the National Molecular Tumour Board with Cancer Trials Ireland, providing access to next generation sequencing and personalised medicines for patients that need it.

Paris 2 Nice

In September 2023, Laura Carroll, Kamilla Flynn, Tanya Knott, Mary Looby, Caitriona O’Brien, Emma Quinn and David Malone will cycle 700km over 6 days from Paris to Nice. All funds raised from this challenge with go towards The SJK Ralston Project to support the National Molecular Tumour Board with Cancer Trials Ireland, providing access to next generation sequencing and personalised medicines for patients that need it.

Gavin Ralston - SJK Foundation

The SJK Ralston Project

The aim of The SJK Ralston Project is to provide access to next generation sequencing (NGS) for patients with cancer of unknown primary and rare cancers. SJK are delighted to support the National Molecular Tumour Board led by Dr Dearbhaile Collins and Cancer Trials Ireland and are members of the steering committee.

Molecular Tumour Boards are a specific type of multi-disciplinary tumour board meeting where patients whom have under gone NGS of their tumour tissue can have their results discussed by a group of experts to investigate if there is any actionable mutations found. With this information the experts will discuss potential targeted therapies and or access to potential clinical trial.

SJK will support by funding NGS testing for CUP patients in the hope the study will be a gate opener for all cancers. In the future, where the cancer began may not be the treatment priority, and instead treatment will be tailored to the unique genetic make up found by genomic profiling. Enabling targeted treatment options specific to the individual patients needs. For patients with cancer of unknown primary and unusual cancers, genetic profiling offers a vital opportunity for targeted treatment. Studies have shown that relevant mutations are observed in 30-85% of patients with cancer of unknown primary.

Genomic profiling is opening up access to clinical trials and access to revolutionary new treatments; unfortunately, despite these benefits, the transition to personalised medicine is slow.

One patient, one test, one at a time.
To support our journey, please

The SJK Ralston Project

The aim of The SJK Ralston Project is to provide access to next generation sequencing (NGS) for patients with cancer of unknown primary and rare cancers. SJK are delighted to support the National Molecular Tumour Board led by Dr Dearbhaile Collins and Cancer Trials Ireland and are members of the steering committee.

Molecular Tumour Boards are a specific type of multi-disciplinary tumour board meeting where patients whom have under gone NGS of their tumour tissue can have their results discussed by a group of experts to investigate if there is any actionable mutations found. With this information the experts will discuss potential targeted therapies and or access to potential clinical trial.

SJK will support by funding NGS testing for CUP patients in the hope the study will be a gate opener for all cancers. In the future, where the cancer began may not be the treatment priority, and instead treatment will be tailored to the unique genetic make up found by genomic profiling. Enabling targeted treatment options specific to the individual patients needs. For patients with cancer of unknown primary and unusual cancers, genetic profiling offers a vital opportunity for targeted treatment. Studies have shown that relevant mutations are observed in 30-85% of patients with cancer of unknown primary.

Genomic profiling is opening up access to clinical trials and access to revolutionary new treatments; unfortunately, despite these benefits, the transition to personalised medicine is slow.

One patient, one test, one at a time. To support our journey, please

Gavin Ralston - SJK Foundation

Gavin

The SJK Ralston project is named in honour of Gavin Ralston. Gavin died in 2019 aged 49 with bowel cancer. He had to self-fund his immunotherapy treatment, it is our hope that in the near future all patients who need to, can access precision diagnostics and targeted therapies without delay.

Gavin Ralston - SJK Foundation

Gavin Ralston

The SJK Ralston project is named in honour of Gavin Ralston. Gavin died in 2019 aged 49 with bowel cancer. He had to self-fund his immunotherapy treatment, it is our hope that in the near future all patients who need to, can access precision diagnostics and targeted therapies without delay.

Gavin Ralston - SJK Foundation
Sarah - SJK Foundation

Sponsor the Journey

Team SJK will be cycling over 700km in 6 days, if you or your company would like to sponsor the journey (km, days) please contact info@sjkfoundation.org
If your company would like to sponsor a day of the journey, team SJK will wear your logo on the jersey.

Sponsor the Journey

Team SJK will be cycling over 700km in 6 days, if you or your company would like to sponsor the journey (km, days) please contact info@sjkfoundation.org
If your company would like to sponsor a day of the journey, team SJK will wear your logo on the jersey.

Corporate Sponsorship

Corporate Sponsorship

If you wish to sponsor the event, please fill the form to contact us

"*" indicates required fields

*

Donate to support SJK Paris2Nice

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Bank Account :

AIB
219 Crumlin Road
IBAN: IE45AIBK93102040728000
BIC: AIBKIE2D
ACCOUNT NO: 40728000
SORT CODE: 931020

If you wish to sponsor the event, please fill the form to contact us

"*" indicates required fields

*

Donate to support SJK Paris2Nice

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Bank Account :

AIB
219 Crumlin Road
IBAN: IE45AIBK93102040728000
BIC: AIBKIE2D
ACCOUNT NO: 40728000
SORT CODE: 931020

Join our Newsletter